Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Strata Critical Medical, Inc. (SRTA)

Strata Q1 2026 revenue rises 87.4% to $67.4 million; 2026 guidance reiterated

Positive Impact 3 of 5 earnings Written later

Strata Critical Medical reported first quarter 2026 results on May 6, 2026, with revenue of $67.4 million, up 87.4% from a year earlier, and net income from continuing operations of $2.4 million compared with a loss of $1.6 million in the prior-year quarter. Adjusted EBITDA was $6.4 million, down from $7.0 million in the fourth quarter of 2025, and the company reiterated its full-year 2026 guidance and completed the bolt-on acquisition of Ohio Valley Perfusion Associates for approximately $1 million.

Key points

  • Total revenue of $67.4 million in Q1 2026 versus $35.9 million in Q1 2025; Logistics revenue rose 32.4% to $47.6 million
  • Net income from continuing operations of $2.4 million versus a $1.6 million loss a year earlier; Adjusted EBITDA of $6.4 million versus $7.0 million in Q4 2025
  • 2026 guidance reiterated: revenue of $260-275 million, Adjusted EBITDA of $29-33 million, free cash flow before aircraft and engine acquisitions of $15-22 million
  • Completed acquisition of Ohio Valley Perfusion Associates for approximately $1 million

The filing

CompanyStrata Critical Medical, Inc. (SRTA)
Form8-K, current report
Filed with the SECMay 6, 2026, 7:09 AM ET
Accession number0001628280-26-030898

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.